GNTA
Genenta Science·NASDAQ
--
--(--)
--
--(--)
GNTA Profile
Genenta Science S.P.A.
A biotech company that developing hematopoietic stem cell fund therapies for solid tumors
Biological Technology
--
12/15/2021
NASDAQ Stock Exchange
9
12-31
Depository Receipts (Ordinary Shares)
Via dell’Annunciata No. 31, 20121 Milan, Italy
--
Genenta Science S.p.A. was incorporated in 2014 under the laws of the Republic of Italy. The company is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors, and they are embarking on a strategic transformation to evolve into a next-generation strategic industry integrator, focusing on the acquisition of private enterprises operated by the national safety regulators envisioned by Italy's "golden power" legislation.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
